You're right there, the money has to come from somewhere.
So I was attempting to do the math, and correct me if Im wrong.. In exchange for Cannvalate paying for the phase 1 clinical trials, IHL is issuing options in stages, which if all are exercised, Cannvalate will own an extra 16% of IHL (after dilution, and not sure how much they current hold), and it would have cost Cannvalate $10,100,000 to do so. Am on the right track?
Can anyone point me to an announcement that talks about how phase 2 trials will be funded?
- Forums
- ASX - By Stock
- Ann: Incannex Presentation - Dr Sud Agarwal - CMO
You're right there, the money has to come from somewhere.So...
-
- There are more pages in this discussion • 162 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add IHL (ASX) to my watchlist
Currently unlisted public company.
The Watchlist
LU7
LITHIUM UNIVERSE LIMITED
Alex Hanly, CEO
Alex Hanly
CEO
SPONSORED BY The Market Online